Literature DB >> 29089331

Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas.

Jingjing Jiao1, Weibo Niu1, Ying Wang2, Keith Baggerly2, Yuanqing Ye3, Xifeng Wu3, Dewitt Davenport4,5, Jose Luis Almeda4,5, Monica M Betancourt-Garcia4, R Armour Forse4,5, Heather L Stevenson6, Gordon P Watt7, Joseph B McCormick7, Susan P Fisher-Hoch7, Laura Beretta8.   

Abstract

We aimed to determine whether aflatoxin dietary exposure plays a role in the high incidence of hepatocellular carcinoma (HCC) observed among Hispanics in South Texas. We measured TP53R249S somatic mutation, hallmark of aflatoxin etiology in HCC, using droplet digital PCR and RFLP. TP53R249S mutation was detected in 3 of 41 HCC tumors from Hispanics in South Texas (7.3%). We also measured TP53R249S mutation in plasma cell-free DNA (cfDNA) from 218 HCC patients and 96 Hispanic subjects with advanced fibrosis or cirrhosis, from South Texas. The mutation was detected only in Hispanic and Asian HCC patients, and patients harboring TP53R249S mutation were significantly younger and had a shorter overall survival. The mutation was not detected in any Hispanic subject with advanced fibrosis or cirrhosis. Genes involved in cell-cycle control of chromosomal replication and in BRCA1-dependent DNA damage response were enriched in HCCs with TP53R249S mutation. The E2F1 family members, E2F1 and E2F4, were identified as upstream regulators. TP53R249S mutation was detected in 5.7% to 7.3% of Hispanics with HCC in South Texas. This mutation was associated with a younger age and worse prognosis. TP53R249S was however not detected in Hispanics in South Texas with cirrhosis or advanced fibrosis. Aflatoxin exposure may contribute to a small number of HCCs in Hispanics in South Texas, but the detection of TP53R249S mutation in plasma cfDNA is not a promising biomarker of risk assessment for HCC in subjects with cirrhosis or advanced fibrosis in this population. Cancer Prev Res; 11(2); 103-12. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29089331      PMCID: PMC5811406          DOI: 10.1158/1940-6207.CAPR-17-0235

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  48 in total

1.  Some traditional herbal medicines, some mycotoxins, naphthalene and styrene.

Authors: 
Journal:  IARC Monogr Eval Carcinog Risks Hum       Date:  2002

2.  Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.

Authors:  Hyun Goo Woo; Xin Wei Wang; Anuradha Budhu; Yun Hee Kim; So Mee Kwon; Zhao-You Tang; Zongtang Sun; Curtis C Harris; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2010-11-19       Impact factor: 22.682

Review 3.  The Role of the Transcription Factor E2F1 in Hepatocellular Carcinoma.

Authors:  Rossella Farra; Gabriele Grassi; Federica Tonon; Michela Abrami; Mario Grassi; Gabriele Pozzato; Nicola Fiotti; Giancarlo Forte; B Dapas
Journal:  Curr Drug Deliv       Date:  2017       Impact factor: 2.565

4.  Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China.

Authors:  Xing-Hua Huang; Lu-Hong Sun; Dong-Dong Lu; Yan Sun; Li-Jie Ma; Xi-Ran Zhang; Jian Huang; Long Yu
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

5.  Epiplakin1 is expressed in the cholangiocyte lineage cells in normal liver and adult progenitor cells in injured liver.

Authors:  Akira Matsuo; Tetsu Yoshida; Takanori Yasukawa; Rika Miki; Kazuhiko Kume; Shoen Kume
Journal:  Gene Expr Patterns       Date:  2011-01-07       Impact factor: 1.224

6.  Mutational hotspot in the p53 gene in human hepatocellular carcinomas.

Authors:  I C Hsu; R A Metcalf; T Sun; J A Welsh; N J Wang; C C Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

7.  Expression patterns of epiplakin1 in pancreas, pancreatic cancer and regenerating pancreas.

Authors:  Tetsu Yoshida; Nobuaki Shiraki; Hideo Baba; Mizuki Goto; Sakuhei Fujiwara; Kazuhiko Kume; Shoen Kume
Journal:  Genes Cells       Date:  2008-05-21       Impact factor: 1.891

8.  TP53 R249S mutations, exposure to aflatoxin, and occurrence of hepatocellular carcinoma in a cohort of chronic hepatitis B virus carriers from Qidong, China.

Authors:  Katarzyna Szymañska; Jian-Guo Chen; Yan Cui; Yun Yun Gong; Paul Craig Turner; Stéphanie Villar; Christopher Paul Wild; Donald Maxwell Parkin; Pierre Hainaut
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-14       Impact factor: 4.254

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  TopHat: discovering splice junctions with RNA-Seq.

Authors:  Cole Trapnell; Lior Pachter; Steven L Salzberg
Journal:  Bioinformatics       Date:  2009-03-16       Impact factor: 6.937

View more
  8 in total

1.  Environmental exposure and clinical correlates of hepatocellular carcinoma in New York City: a case only study.

Authors:  Hui-Chen Wu; Jing Shen; Abby Siegel; Regina M Santella
Journal:  Cancer Causes Control       Date:  2021-09-08       Impact factor: 2.506

2.  High Prevalence of Hepatic Fibrosis, Measured by Elastography, in a Population-Based Study of Mexican Americans.

Authors:  Gordon P Watt; Miryoung Lee; Jen-Jung Pan; Michael B Fallon; Rohit Loomba; Laura Beretta; Joseph B McCormick; Susan P Fisher-Hoch
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-11       Impact factor: 11.382

Review 3.  The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma.

Authors:  Francesca Pezzuto; Luigi Buonaguro; Franco Maria Buonaguro; Maria Lina Tornesello
Journal:  Int J Mol Sci       Date:  2018-03-28       Impact factor: 5.923

4.  Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: Prevalence and risk factors.

Authors:  Jingjing Jiao; Gordon P Watt; Heather L Stevenson; Tiffany L Calderone; Susan P Fisher-Hoch; Yuanqing Ye; Xifeng Wu; John M Vierling; Laura Beretta
Journal:  Hepatol Commun       Date:  2018-04-27

5.  Analysis of TP53 aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A cross-sectional study (2016-2017).

Authors:  Christian S Alvarez; Jeremy Ortiz; Giovanna Bendfeldt-Avila; Yi Xie; Mingyi Wang; Dongjing Wu; Herbert Higson; Elisa Lee; Kedest Teshome; Joaquin Barnoya; David E Kleiner; John D Groopman; Roberto Orozco; Katherine A McGlynn; Eduardo Gharzouzi; Michael Dean
Journal:  Health Sci Rep       Date:  2020-05-06

6.  Aflatoxin B1 exposure and liver cirrhosis in Guatemala: a case-control study.

Authors:  Christian S Alvarez; Elisa Hernández; Kira Escobar; Carmen I Villagrán; María F Kroker-Lobos; Alvaro Rivera-Andrade; Joshua W Smith; Patricia A Egner; Mariana Lazo; Neal D Freedman; Eliseo Guallar; Michael Dean; Barry I Graubard; John D Groopman; Manuel Ramírez-Zea; Katherine A McGlynn
Journal:  BMJ Open Gastroenterol       Date:  2020-07

7.  Increase in aflatoxin exposure in two populations residing in East and West Texas, United States.

Authors:  Kathy S Xue; Lili Tang; Chwan Li Shen; Bradley H Pollock; Fernando Guerra; Timothy D Phillips; Jia-Sheng Wang
Journal:  Int J Hyg Environ Health       Date:  2020-11-13       Impact factor: 5.840

8.  Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.

Authors:  Jingjing Jiao; Jessica I Sanchez; Erika J Thompson; Xizeng Mao; Joseph B McCormick; Susan P Fisher-Hoch; P Andrew Futreal; Jianhua Zhang; Laura Beretta
Journal:  Int J Mol Sci       Date:  2021-07-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.